Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Hepatocellular × Tirapazamine × Clear all

Phase

Phase 1/2 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1 Recurrence 1 Ovarian Neoplasms 1 Limited Stage Small Cell Lung Cancer 1 Head and Neck Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Hepatocellular 1 Alveolar Childhood Rhabdomyosarcoma 1

Interventions

Sorafenib 62 Bevacizumab 59 lenvatinib 52 durvalumab 35 atezolizumab 27 sintilimab 26 Nivolumab 26 pembrolizumab 24 Oxaliplatin 24 tremelimumab 22 tislelizumab 22 Fluorouracil 21 apatinib 20 Radiosurgery 19 camrelizumab 18 regorafenib 15 cabozantinib 15 Doxorubicin 15 Leucovorin 14 Capecitabine 13 Radiotherapy 12 Folfox protocol 12 donafenib 11 Gemcitabine 10 Cisplatin 10 Immune Checkpoint Inhibitors 9 Erlotinib Hydrochloride 9 toripalimab 8 Neoadjuvant Therapy 8 Immunotherapy 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03145558 2024-11-22

TATE

Teclison Ltd.

Phase 2 Terminated

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡